Biogen Idec Gets 483 for Overlooking Particles

Drug GMP Report
A A
The FDA handed Biogen Idec’s Cambridge, Mass. facility a Form 483 after the company released a drug substance destined for compounding that contained white particles.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $135.00